Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice
Darko Bosnakovski, … , Dawn A. Lowe, Michael Kyba
Darko Bosnakovski, … , Dawn A. Lowe, Michael Kyba
Published April 6, 2020
Citation Information: J Clin Invest. 2020;130(5):2465-2477. https://doi.org/10.1172/JCI133303.
View: Text | PDF
Research Article Muscle biology Neuroscience

Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice

  • Text
  • PDF
Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is caused by loss of repression of the DUX4 gene; however, the DUX4 protein is rare and difficult to detect in human muscle biopsies, and pathological mechanisms are obscure. FSHD is also a chronic disease that progresses slowly over decades. We used the sporadic, low-level, muscle-specific expression of DUX4 enabled by the iDUX4pA-HSA mouse to develop a chronic long-term muscle disease model. After 6 months of extremely low sporadic DUX4 expression, dystrophic muscle presented hallmarks of FSHD histopathology, including muscle degeneration, capillary loss, fibrosis, and atrophy. We investigated the transcriptional profile of whole muscle as well as endothelial cells and fibroadiopogenic progenitors (FAPs). Strikingly, differential gene expression profiles of both whole muscle and, to a lesser extent, FAPs, showed significant overlap with transcriptional profiles of MRI-guided human FSHD muscle biopsies. These results demonstrate a pathophysiological similarity between disease in muscles of iDUX4pA-HSA mice and humans with FSHD, solidifying the value of chronic rare DUX4 expression in mice for modeling pathological mechanisms in FSHD and highlighting the importance FAPs in this disease.

Authors

Darko Bosnakovski, Ahmed S. Shams, Ce Yuan, Meiricris T. da Silva, Elizabeth T. Ener, Cory W. Baumann, Angus J. Lindsay, Mayank Verma, Atsushi Asakura, Dawn A. Lowe, Michael Kyba

×

Figure 3

FSHD signature gene expression in muscle from iDUX4pA-HSA mice.

Options: View larger image (or click on image) Download as PowerPoint
FSHD signature gene expression in muscle from iDUX4pA-HSA mice.
(A) The ...
(A) The DUX4 score shows enrichment of DUX4 early target genes in muscles from iDUX4pA-HSA mice induced for 2 and 16 weeks. A list of DUX4 early affected genes was identified in iC2C12-DUX4 cells after 4 hours of DUX4 induction (13). (B) Gene set enrichment analysis (GSEA) of differentially expressed genes (DEG) at 2 and 16 weeks in induced mice and FSHD biopsies identified by Wang et al. (25). (C) GSEA of differentially expressed genes at 2 and 16 weeks in induced mice and FSHD biopsies identified by Tasca et al. (24). (D) Venn diagram for common differentially expressed genes in patients with FSHD from the Wang et al. data set (25) and iDUX4pA-HSA mice at 2 and 16 weeks and top enriched KEGG pathways. (E) Venn diagram shows the number of specific and commonly expressed genes in patients with FSHD from the Tasca data set (24) and iDUX4pA-HSA mouse, and top KEGG pathways.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts